RxDoctor Payments Data

Fredric Ginsberg, MD

Cardiovascular Disease · Cherry Hill, NJNPI 1528156981

Payments from drug & device makers

$8,822in general payments, 2019–2025

Across 69 payments — averaging $127.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ZOLL Respicardia, Inc.$8K
  • Amgen$207
  • Johnson & Johnson$191
  • Philips North America LLC$74
  • Novartis$61
  • Astellas Pharma US Inc$56
  • plus $377 from 12 others

What the payments were for

  • Food & beverage$965100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$8,822 in reported general payments places this provider in the 75th percentile of 1,006 cardiovascular disease providers in New Jersey.

See all cardiovascular disease providers in New Jersey

Medicare billing

Part B allowed, 2024
$250,010
Medicare patients
777
Services billed
2,867

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban182$250,487
XareltoRivaroxaban64$92,005
EntrestoSacubitril/Valsartan34$52,991
Repatha SureclickEvolocumab37$48,302
JardianceEmpagliflozin24$34,612
FarxigaDapagliflozin Propanediol33$31,570
Praluent PenAlirocumab11$10,808
Carvedilol ErCarvedilol Phosphate13$9,281
Rosuvastatin Calcium300$5,347
Metoprolol Succinate311$4,916
Atorvastatin Calcium280$3,366
Ranolazine ErRanolazine18$2,648
Valsartan50$2,012
Candesartan Cilexetil15$1,994
Omega-3 Acid Ethyl Esters12$1,847

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$51$250,487182 claims
Johnson & JohnsonXarelto$191$92,00564 claims
NovartisEntresto$61$52,99134 claims
Boehringer IngelheimJardiance$27$34,61224 claims
AstraZenecaFarxiga$55$31,57033 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,006 cardiovascular disease providers in New Jersey.

Other cardiovascular disease in Cherry Hill

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →